Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced a $33 million Series B on the heels of the adoption of its Generative AI platform (GENEVA OS™) by healthcare institutions, data platforms, research institutions, life sciences companies and more. The funding was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures.

Atropos Health is the developer of the first physician consultation service powered by research-grade real-world data. Using millions of anonymized patient records, Atropos helps providers answer clinical questions that have fallen through the cracks of the evidence-based literature. By leveraging insights from free-text notes and other non-standard data entries that often go overlooked, Atropos empowers more robust research and effective care delivery.